Evoke Pharma Inc Annual Revenue from Contract with Customer, Excluding Assessed Tax in USD from 2020 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Evoke Pharma Inc quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from 2020 to 2023.
- Evoke Pharma Inc Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2024 was $2.65M, a 69.8% increase year-over-year.
- Evoke Pharma Inc Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending September 30, 2024 was $8.62M, a 100% increase year-over-year.
- Evoke Pharma Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $5.18M, a 107% increase from 2022.
- Evoke Pharma Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $2.51M, a 55% increase from 2021.
- Evoke Pharma Inc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $1.62M, a 6929% increase from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Growth (%)